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a  b  s  t  r  a  c  t
The  main  bacterium  associated  with  skin  infection  is Staphylococcus  aureus,  occurring  especially  in  infec-
tions  acquired  via  surgical  wounds,  commonly  leading  to lethal  hospital-acquired  infections,  emphasizing
the  importance  of  identifying  new  antimicrobial  compounds.  Among  them,  cyclotides  have  gained  inter-
est  due  to  their  high  stability  and  multifunctional  properties.  Here,  cycloviolacin  2 (CyO2)  and  kalata
B2  (KB2)  were  evaluated  to determinate  their  anti-staphylococcal  activities  using  a subcutaneous  infec-eywords:
yclotides
alata
ound infections
hagocytosis
. aureus
tion  model.  Anti-staphylococcal  activities  of 50 mM  for  KB2  and  25  mM  for  CyO2  were  detected  with  no
cytotoxic  activities  against  RAW  264.7  monocytes.  In  the  in  vivo  assays,  both  cyclotides  reduced  bacterial
load  and  CyO2  demonstrated  an increase  in the  phagocytosis  index,  suggesting  that  the  CyO2  in vivo  anti-
staphylococcal  activity  may  be  associated  with  phagocytic  activity,  additionally  to  direct  anti-pathogenic
activity.
©  2014  Elsevier  Inc.  All  rights  reserved.ntroduction
The skin is the largest and the most exposed organ of the human
ody [26]. Although it is extremely effective in protecting host-
rganisms against external environmental threats, skin infections
re common and may  be caused by bacteria, fungi or viruses [26,28].
he main bacterium associated with skin infections is Staphy-
ococcus aureus [2,27]. The majority of infections can be simply
reated, but some are less tractable, especially those associated with
urgical wounds, which are the most common hospital-acquired
nfections and a major cause of morbidity and mortality [9,16].
hese infections are increasingly caused by pathogens that are
esistant to conventional treatments, which highlights the impor-
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196-9781/© 2014 Elsevier Inc. All rights reserved.tance of identifying new and more effective antimicrobial therapies
[1,32].
Antimicrobial peptides (AMPs) have emerged as a promising
new therapy with potential for the treatment of infectious dis-
eases [1,32]. Among AMPs, cyclotides have shown great promise
in a range of drug design applications. These head-to-tail cyclized
peptides, originally isolated from plants, incorporate six conserved
cysteine residues in their structure, which form three intercon-
nected disulﬁde bonds organized in a cyclic cystine knot (CCK)
motif. This motif makes cyclotides highly stable and has generated
interest in them as peptide-based scaffolds for designing medicines
[6,10,19]. The cyclotides can be divided into mainly two subfam-
ilies known as Möbius (Fig. 1A) and bracelet cyclotides (Fig. 1B);
the main characteristic that distinguishes one from the other is the
presence of a conserved cis-proline residue in loop 5 of the Möbius
subfamily, creating a twist in the circular backbone [4,8,10,29,40].
Here, the cyclotides cycloviolacin O2 (CyO2) and kalata B2
(KB2), respectively members of the bracelet and Möbius sub-
families (Fig. 1), were evaluated to characterize their cytotoxic
and anti-staphylococcal activities against S. aureus in an in vitro
microdilution assay and also in vivo using in a subcutaneous wound
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Fig. 1. Sequences and structures of cyclotides – (A) cycloviolacin O2 (CyO2) and (B) kalata B2 (KB2). All cyclotides contain six cysteines (I-VI) connected by disulﬁde bonds
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n  Möbius cyclotides that gives a conceptual backbone twist resembling a Möbius s
nfection model. This study is the ﬁrst report deﬁning the efﬁcacy
f cyclotides in an in vivo infection model.
aterials and methods
eptides
The peptides used in this study, CyO2 and KB2, were
xtracted from the aerial parts of the plants Viola odorata
CyO2) and Oldenlandia afﬁnis (KB2) with a 1:1 solution of
ichloromethane/methanol for 12 h. The extract was  partitioned
ith water and the methanol/water fraction was rotary evaporate
o remove the methanol and lyophilized. The dried product was
esuspended in water and puriﬁed by RT-preparative HPLC using a
18 column. Peptide masses were analysed using an ES-TOF micro-
ass LCT mass spectrometer [7].
actericidal microdilution assays
Minimum inhibitory concentrations (MICs) of the cyclotides
gainst S. aureus ATCC 25923 were determined using a standard-
zed dilution method according to NCSLA guidelines [39]. A single
acterial colony was inoculated in Mueller-Hinton broth (MH)
Himedia, India) and incubated for 12 h at 37 ◦C. Overnight-cultured
. aureus was transferred to MH medium and cultured to expo-
ential phase (OD600 of ∼0.6). The culture was  centrifuged and
esuspended in sterile PBS and adjusted to a ﬁnal amount of
 × 105 colony-forming units (CFU) mL−1 by use of the equation
FU mL−1 = OD600 nm × 2.5 × 108 [35]. For MIC  determination, pep-
ides were applied at various concentrations (1–200 M)  from a
tock solution. Ten microliters of each concentration of peptide
olution was added to each corresponding well of a 96-well plate
Becton & Dickinson, USA) and 90 L of bacteria (1 × 105) in MH
edium was added. The polypropylene plates (TPP, Switzerland)
ere incubated at 37 ◦C for 24 h. MICs were determined as the low-
st tested concentration that leads to complete inhibition (100%)
ompared to the negative control group [33].
nimalsC57BL/6 mice weighting 18–22 g were used in this study, pro-
ided by the animal facility of the Catholic University of Brasilia.
ll animals were housed in separate cages under a constantectively. The two  subfamilies differ by the presence of conserved cis-Pro in loop 5
temperature (22 ◦C) and humidity, with a 12-h light/dark cycle and
access to food and water ad libitum throughout the study. The mice
were euthanized by CO2 or ether inhalation at the end of the exper-
iments. All procedures including care and handling of the animals
were approved by the Ethics Committee of the Catholic University
of Brasilia number 005/13.
Cell cytotoxicity assays
Murine monocytes RAW 264.7 cells (Rio de Janeiro Cell Bank)
were seeded in 96-well microtiter plates in a concentration
of 1.0 × 105 cells per well, in DMEM medium, supplemented
with various concentrations of the tested cyclotides (0.3–15 M).
After 24 and 48 h incubation, a 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay was
performed. Brieﬂy, 60% of the medium was removed, and 10 L of
MTT  (5 mg  mL−1) (Sigma, USA) solution was  added to each well and
the plate was incubated for 4 h in 5% CO2 at 37 ◦C. The blue form-
azan product produced was dissolved by the addition of 100 L
of 100% DMSO (Mallinckrodt, Germany) per well. Plates were then
gently swirled for 5 min  at room temperature to dissolve the precip-
itate. The absorbance was monitored at 575 nm using a microplate
spectrophotometer (Bio-Tek, USA). Cytotoxicity was  determined as
a percentage of the maximum value after subtracting the back-
ground. The results were stated as the percentage of each sample
matched to the negative control (PBS buffer, pH 7.4) and cell cul-
ture was incubated in a lysis buffer (10 mM Tris, pH 7.4, 1 mM
ethylenediamine tetraacetic acid (EDTA), and 0.1% Triton X-100)
[39].
Induction of peritonitis and peritoneal cell collection
Peritonitis was induced as described by Leendertse et al. [23].
Mice were injected intraperitoneally with 200 L of 3% thioglycol-
late solution. Peritonitis was  induced 6 h after injection [23]. After
this period, mice were anesthetized by 10% ketamine (80 mg kg−1)
(Agener Union – Brazil) and xylazine (10 mg  kg−1) (Agener Union
– Brazil), euthanasiated, and a peritoneal lavage was performed
with 5 mL  of RPMI 1670 medium using an 18-gauge needle. After
collection of peritoneal lavage ﬂuid (PLF), cellular content was
immediately placed on ice. The numbers of total cells and neu-
trophils were counted using a microscope.
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hagocytosis assays
Phagocytosis assays were conducted using neutrophils (105
ells per well). Controls (untreated and treated with DMSO 2.5%
nd gentamicin 15 M)  and treatments with the previously deter-
ined cyclotide MIC  concentration were conducted in RPMI 1640
edium. The cells were infected with S. aureus at a multiplicity of
nfection (MOI) of 1:1 and incubated for 90 min. Following incuba-
ion, the cells were centrifuged, placed on slides and stained with
ast panoptic dye [34]. For neutrophil phagocytosis assay assess-
ents, at least 100 cells on each slide with or without phagocytosis
ere counted. Additionally, the number of phagocytosed particles
nd phagocytic index was calculated. In all experiments the phago-
ytosis conﬁrmatory counts were conducted by an independent
bserver. The phagocytic index (PI) was calculated using the
ormula: PI equals the percentage of cell phagocytosis multiplied
y the average number of particles phagocytosed by each cell.
urine surgical wound infection model
The murine surgical wound infection model was  performed as
escribed by McRipley and Whitney [24] with minor modiﬁcations.
ice (n = 5/group) were anesthetized, their dorsal surface shaved
nd the surgical area disinfected with 70% ethanol. A puncture was
erformed on the dorsal surface using 6-mm punch biopsy needles
Stiefel Laboratories, UK), and then 10 L of S. aureus ATCC 25923
uspension (2 × 109 mL−1; previously cultured as described in the
ection on bactericidal microdilution assays) was introduced into
he puncture wound, and the skin was closed with one silk suture
41]. Wounds were treated every 24 h with 20 L of a solution
ig. 2. Effect of cyclotides CyO2 (A) and KB2 (B) on viability of murine cell line RAW 264.7. 
alues represent the mean ± SD and data were analyzed by one-way ANOVA and Bonferro
acterial load of the wound from the C57BL/6 mice infected with S. aureus ATCC 25923 after
nd  treated with: DMSO 2.5%, Vetagls® (gentamicin 5 mg  kg−1, sulphanilamide 50 mg  kg−
B2  (0.75 mg kg−1, 1.5 mg  kg−1, 3.0 mg  kg−1). Values represent the mean ± SD and data w
 < 0.05; ** p < 0.01; *** p < 0.001 compared to the negative control. For the phagocytosis
ontrols: DMSO (2.5%), gentamicin (15 M)  or DMEM;  and treated with: (E) CyO2 (25 M
ne-way ANOVA and Bonferroni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untretides 63 (2015) 38–42
containing 0.75–3 mg  kg−1 of cyclotide. Vetaglos® (gentamicin
0.5%, sulfanilamide 5% and sulfadiazine 5%) ointment (Vetnil,
Brazil) was used as a positive control and PBS as negative control.
Mice were euthanized 7 days post-surgery; the wounded mus-
cle tissue was  excised, weighed, and homogenized in 1 mL  of PBS.
Serial homogenate dilutions were plated in triplicate on mannitol
salt agar (Himedia, India) and the results were stated as CFU g−1 of
tissue [18,35].
Statistical analysis
Data are presented as mean ± SD of all samples. Values of p < 0.05
were considered statistically signiﬁcant. GraphPad Prism software
v5.0 (GraphPad Software, USA) was used for all statistical analyses
[33].
Results
In vitro antibacterial activity
The activities of the cyclotides against S. aureus were evalu-
ated in vitro and MICs determined by microdilution tests (data not
shown). The MIC  for KB2 was 50 M and that for CyO2 was 25 M.
Effects of cyclotides in cell viability/metabolismCytotoxicity evaluation against RAW 264.7 cells for CyO2
(Fig. 2A) and KB2 (Fig. 2B) did not show signiﬁcant deleterious activ-
ities at the concentrations tested when compared with the control,
demonstrating that these peptides show no cytotoxicity to RAW
Cells were incubated for 24 and 48 h with CyO2 (27–438 nM), and KB2 (29–465 nM).
ni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untreated group. Recovery of
 6 days of treatment. The wounds were inoculated with 2×109 cells mL−1 of bacteria
1, sulfadiazine 50 mg  kg−1); (C) CyO2 (0.75 mg kg−1, 1.5 mg kg−1, 3.0 mg  kg−1); (D)
ere analysed by two-way ANOVA and Tukey’s test, with p < 0.05 as signiﬁcant: *
 assay, neutrophils extracted from healthy animals were incubated for 1.5 h with
)  or (F) KB2 (50 M).  Values represent the mean ± SD and data were analysed by
ated group.
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64.7 cells, at the evaluated concentrations (CyO2 ranging from
37.8 to 27.4 nM and KB2 ranging from 465.2 to 29.1 nM).
eriﬁcation of bacterial burdens recovered from wounds
Mice treated with 0.75 mg  kg−1 of CyO2 showed a slight reduc-
ion in bacterial load of 108 to ∼107. When treated with 1.5 and
.0 mg  kg−1, the bacterial load was reduced to ∼106 (Fig. 2C). In ani-
als treated with 6.0 mg  kg−1 of CyO2, a clear decrease in bacterial
oad of 108–105 was observed (data not shown). The infected mice
reated with KB2 showed a decrease in bacterial load of 108 to ∼106
n all tested concentrations (0.75, 1.5 and 3.0 mg  kg−1) (Fig. 2D).
valuation of phagocytosis
To evaluate possible indirect antibacterial activity through stim-
lation of the host, we measured the activity of cyclotides on
he phagocytic activity of neutrophils following S. aureus infec-
ion. Neutrophils treated with KB2 (Fig. 2E) showed no variation
n the phagocytic index compared with controls. However, CyO2
ncreased the phagocytic index by ∼545% (Fig. 2F), suggesting that
t has the capability of stimulating phagocytosis of S. aureus by
eutrophils.
iscussion
With the rapidly increasing prevalence of multidrug-resistant
acteria and the scarcity of new antibiotic research in the pharma-
eutical industry, the use of AMPs could be a promising alternative
o conventional antibiotic treatments. AMPs are multifunctional
ediators of the innate immune response with direct antimicrobial
nd immunomodulatory activities. Among AMPs, cyclotides are
otable for being small cyclic peptides with six conserved cysteine
esidues that form three interconnected disulﬁde bonds, thereby
iving them greater stability than linear AMPs [13,17,30]. Thus,
yclotides could potentially overcome some of the limitations of
eptides as drugs, such as sensitivity to proteolytic degradation
12,13,30].
In the present study the antibacterial activities of KB2 and CyO2
gainst S. aureus ATCC 25923 were evaluated. CyO2 had the best
nti-staphylococcal activity in vitro whereas KB2 had only slightly
ower potency. In the literature there are two  studies in which
yclotides were tested against S. aureus.  Tam et al. [36], reported
hat KB1, circulin A and B, and cyclopsychotride showed MICs
gainst S. aureus of 0.26 M,  0.19 M,  13.5 M and 39 M,  respec-
ively under low salt conditions but no activity under physiological
alt conditions [36]. Pranting et al. [31] evaluated CyO2, KB1, KB2,
aby A and D for activity against S. aureus,  but no deleterious activi-
ies against S. aureus were obtained using the radial diffusion assay,
erformed with 4 × 106 CFU in a culture medium based on sodium
hosphate buffer containing 0.03% (w/v) trypticase soy broth and
% agarose, with wells made using a 3 mm gel punch added 5 L of
ample, then incubated for 18–24 h, 37 ◦C. However, in microdi-
ution assays, these cyclotides inhibited S. aureus growth: CyO2
>50 M),  KB1 (>100 M),  KB2 (35 M),  Vaby A and D (>90 M)
31].
Given the conﬁrmation in our study of the anti-staphylococcal
ctivity of cyclotides KB2 and CyO2, we tested them for effects
n cell viability of murine RAW 264.7 monocytes and found
hat low doses did not cause any harmful effect. Otherwise any
valuation was performed at higher concentrations. Only KB2
howed slight cytotoxicity at higher doses (>15 M)  (data not
hown). Similar data were obtained by Grundemann et al. [11],
here O. afﬁnis extract and KB1 (1.8–14.0 M)  reduced peripheral
lood mononucleated cell (PBMC) proliferation. That study showedtides 63 (2015) 38–42 41
that at concentrations of 1.8–14 M a dose-dependent correlation
decrease in cell proliferation was  observed.
Since in vitro antibacterial activity, but no mammalian cytotox-
icity, was observed in the two cyclotides tested here, the next step
was to evaluate their in vivo anti-staphylococcal activity using a
surgical S. aureus wound infection model. To our knowledge, there
has been no previous report of cyclotide antimicrobial activity in an
animal infection model. The cyclotides showed similar responses,
and both decreased bacterial load. Interestingly, a progressive dose
response was  not observed, probably due to the low concentrations
tested. A similar phenomenon was  observed with the antimicrobial
peptide PXL150, which all tested concentrations showed activity
toward S. aureus [25].
A number of other studies have reported in vivo antibacterial
activity of AMPs using the surgical wound model used here. For
example, coprisin (5 mg  kg−1), in addition to reducing the bacte-
rial load, accelerated the wound healing process [21]. In another
study, PEP35 exhibited poor antimicrobial activity in vitro, with
MIC50 values for various clinical strains of S. aureus isolates of
approximately 500 g mL−1. Nevertheless, this peptide showed
immunomodulatory activity, and when tested in vivo in the sur-
gical wound model, reduced the bacterial load to approximately
102 CFU g−1 tissue, probably recruiting neutrophils to the infection
site [22]. In another study, epinecidin peptide-1 (EPI-1) was  evalu-
ated against MRSA (106 CFU), with treatments placed on the wound
5 min  after infection, which was covered after 30 min to prevent
interference by the animal [15]. Groups treated with EPI-1 showed
an improved survival rate with a decrease in bacterial load of 106 to
∼20 to CFU g−1 tissue [15]. In a study using the same methodology,
the pardaxin peptide (GE33) led to complete bacterial clearance in a
surgical wound model infected with 106 CFU of S. aureus.  The activ-
ities of the cyclotides tested here are comparable to those reported
in these previous studies.
To observe whether the in vivo effects of the cyclotides could
be related simply to direct antibacterial activity or also to addi-
tional indirect host activity, a phagocytosis assay was performed
to assess the stimulation of neutrophils to increase S. aureus
phagocytosis. KB2 showed no change compared with the controls,
suggesting that the mechanism of action is based predominantly
on bactericidal activity. By contrast, CyO2 showed an increase
in phagocytic index of approximately 550%, suggesting that its
in vivo activity against S. aureus might be associated with both
bactericidal and phagocytic induction in the host animal. It is
interesting that this dual strategy is not seen with KB2. Other
antimicrobial peptides have been reported to induce phagocytic
activity, such as LL-37, which was  able to enhance phagocytosis
of opsonized Gram-negative and Gram-positive bacteria, besides
improving the phagocytosis of non-opsonized Escherichia coli in
human macrophages [38]. Another peptide that leads to improved
phagocytic activity in macrophages is hLF1-11, which was shown
to improve the phagocytosis of not only S. aureus,  but also Candida
albicans [37].
In conclusion, CyO2 and KB2 might represent a starting point
for a novel therapeutic approach for the local treatment of infec-
tions. Cyclotides can be produced recombinantly [3] or chemically
[5], which opens new frontiers for the production of cyclotide-
based medicines. The exceptional stability and cell penetrating
properties of cyclotides make them possible scaffolds for the
grafting of known active peptides for the engineering of peptide-
based drugs [20]. Such an approach might be used to enhance
the natural antimicrobial activity of the cyclotide framework,
which appears to be driven mainly by membrane binding and
disruption [14]. However, more studies are needed to evalu-
ate the applicability of these cyclic AMPs as well as to shed
additional light on their in vivo antibactericidal mechanism of
action.
4 l. / Pep
C
w
F
v
A
d
A
E
d
p
C
D
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[2 I.C.M. Fensterseifer et a
onﬂicts of interest
The authors declare no conﬂicts of interest, ﬁnancial or other-
ise, in relation to this manuscript.
unding
This work was supported by Conselho Nacional de Desen-
olvimento Cientíﬁco e Tecnológico (CNPq), Coordenac¸ ão de
perfeic¸ oamento de Pessoal de Nível Superior (CAPES), Fundac¸ ão
e Amparo a Pesquisa do Distrito Federal (FAPDF), Fundac¸ ão de
poio ao Desenvolvimento do Ensino, Ciência e Tecnologia do
stado de Mato Grosso do Sul (FUNDECT) and Universidade Católica
e Brasília (UCB). Work at the University of Queensland was  sup-
orted by a grant from the National Health and Medical Research
ouncil (APP1028509) and a UQ Researcher Exchange Travel Grant.
JC is a NHMRC Professorial Fellow (APP1026501).
eferences
[1] Akova M.  Emerging problem pathogens: a review of resistance patterns over
time. Int J Infect Dis 2006;10:S3–8.
[2] Aly R. Microbial infections of skin and nails. In: Baron S, editor. Medical micro-
biology. 4th ed. 1996. Galveston, TX.
[3] Austin J, Kimura RH, Woo  YH, Camarero JA. In vivo biosynthesis of an
Ala-scan library based on the cyclic peptide SFTI-1. Amino Acids 2010;38:
1313–22.
[4] Chen B, Colgrave ML,  Daly NL, Rosengren KJ, Gustafson KR, Craik DJ. Isolation
and characterization of novel cyclotides from Viola hederaceae: solution struc-
ture and anti-HIV activity of vhl-1, a leaf-speciﬁc expressed cyclotide. J Biol
Chem 2005;280:22395–405.
[5] Craik DJ, Conibear AC. The chemistry of cyclotides. J Org Chem
2011;76:4805–17.
[6] Craik DJ, Daly NL, Bond T, Waine C. Plant cyclotides: a unique family of cyclic
and knotted proteins that deﬁnes the cyclic cystine knot structural motif. J Mol
Biol  1999;294:1327–36.
[7] Daly NL, Clark RJ, Craik DJ. Disulﬁde folding pathways of cystine knot pro-
teins. Tying the knot within the circular backbone of the cyclotides. J Biol Chem
2003;278:6314–22.
[8] Daly NL, Clark RJ, Plan MR,  Craik DJ. Kalata B8, a novel antiviral circular pro-
tein, exhibits conformational ﬂexibility in the cystine knot motif. Biochem J
2006;393:619–26.
[9] Eckmann C, Dryden M.  Treatment of complicated skin and soft-tissue infections
caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and
vancomycin. Eur J Med  Res 2010;15:554–63.
10] Gruber CW,  Cemazar M,  Anderson MA,  Craik DJ. Insecticidal plant cyclotides
and  related cystine knot toxins. Toxicon: Off J Int Soc Toxinol 2007;49:
561–75.
11] Grundemann C, Koehbach J, Huber R, Gruber CW.  Do plant cyclotides have
potential as immunosuppressant peptides. J Nat Prod 2012;75:167–74.
12] Gunasekera S, Foley FM,  Clark RJ, Sando L, Fabri LJ, Craik DJ, et al. Engineering
stabilized vascular endothelial growth factor-A antagonists: synthesis, struc-
tural characterization, and bioactivity of grafted analogues of cyclotides. J Med
Chem 2008;51:7697–704.
13] Henriques ST, Craik DJ. Cyclotides as templates in drug design. Drug Discov
Today 2010;15:57–64.
14] Henriques ST, Craik DJ. Importance of the cell membrane on the mechanism of
action of cyclotides. ACS Chem Biol 2012;7:626–36.
15] Huang HN, Rajanbabu V, Pan CY, Chan YL, Wu CJ, Chen JY. Use of the antimicro-
bial peptide epinecidin-1 to protect against MRSA infection in mice with skin
injuries. Biomaterials 2013;34:10319–27.
16] Hwang JH, Lee JH, Moon MK,  Kim JS, Won  KS, Lee CS. The efﬁcacy and safety
of  arbekacin and vancomycin for the treatment in skin and soft tissue MRSA
infection: preliminary study. Infect Chemother 2013;45:62–8.
17] Ireland DC, Colgrave ML,  Craik DJ. A novel suite of cyclotides from Viola odorata:
sequence variation and the implications for structure, function and stability.
Biochem J 2006;400:1–12.
[tides 63 (2015) 38–42
18] Jacobsen F, Baraniskin A, Mertens J, Mittler D, Mohammadi-Tabrisi A, Schu-
bert S, et al. Activity of histone H1.2 in infected burn wounds. J Antimicrob
Chemother 2005;55:735–41.
19] Jennings CV, Rosengren KJ, Daly NL, Plan M,  Stevens J, Scanlon MJ,  et al. Isolation,
solution structure, and insecticidal activity of kalata B2, a circular protein with
a  twist: do mobius strips exist in nature. Biochemistry 2005;44:851–60.
20] Koehbach J, O’Brien M,  Muttenthaler M,  Miazzo M,  Akcan M,  Elliott AG, et al.
Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor
ligand design. Proc Natl Acad Sci U S A 2013;110:21183–8.
21] Lee J, Han SY, Ji AR, Park JK, Hong IH, Ki MR,  et al. Antimicrobial effects of
coprisin on wounds infected with Staphylococcus aureus in rats. Wound Repair
Regen 2013.
22] Lee JC, Greenwich JL, Zhanel GG, Han X, Cumming A, Saward L, et al. Modulation
of  the local neutrophil response by a novel hyaluronic acid-binding peptide
reduces bacterial burden during staphylococcal wound infection. Infect Immun
2010;78:4176–86.
23] Leendertse M,  Willems RJ, Giebelen IA, van den Pangaart PS, Wiersinga
WJ,  de Vos AF, et al. TLR2-dependent MyD88 signaling contributes to
early host defense in murine Enterococcus faecium peritonitis. J Immunol
2008;180:4865–74.
24] McRipley RJ, Whitney RR. Characterization and quantitation of experimen-
tal surgical-wound infections used to evaluate topical antibacterial agents.
Antimicrob Agents Chemother 1976;10:38–44.
25] Myhrman E, Hakansson J, Lindgren K, Bjorn C, Sjostrand V, Mahlapuu M.  The
novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue
infections. Appl Microbiol Biotechnol 2013;97:3085–96.
26] Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and
disease. Nat Rev Immunol 2009;9:679–91.
27] Nichols RL, Florman S. Clinical presentations of soft-tissue infections and sur-
gical site infections. Clin Infect Dis 2001;33(Suppl. 2):S84–93.
28] O’Dell ML.  Skin and wound infections: an overview. Am Fam Phys
1998;57:2424–32.
29] Pelegrini PB, Quirino BF, Franco OL. Plant cyclotides: an unusual class of defense
compounds. Peptides 2007;28:1475–81.
30] Pinto MFS, Almeida RG, Porto WF,  Fensterseifer ICM, Lima LA, Dias SC, et al.
Cyclotides: from gene structure to promiscuous multifunctionality. Evid-Based
Complement Alternat Med  2012;17:40–53.
31] Pranting M,  Loov C, Burman R, Goransson U, Andersson DI. The cyclotide
cycloviolacin O2 from Viola odorata has potent bactericidal activ-
ity against Gram-negative bacteria. J Antimicrob Chemother 2010;65:
1964–71.
32] Prates MV,  Bloch Jr C. Peptídeos antimicrobianos: uma alternativa no com-
bate a microrganismos resistentes. Biotecnologia Ciência e Desenvolvimento
2000;17:30–6.
33] Silva ON, Porto WF,  Migliolo L, Mandal SM,  Gomes DG, Holanda HHS, et al.
Cn-AMP1: a new promiscuous peptide with potential for microbial infections
treatment. Pept Sci 2012;48:322–31.
34] Singh PK, Shiha MJ,  Kumar A. Antibacterial responses of retinal Muller glia:
production of antimicrobial peptides, oxidative burst and phagocytosis. J Neu-
roinﬂamm 2014;11:33.
35] Steinstraesser L, Hirsch T, Schulte M,  Kueckelhaus M,  Jacobsen F, Mersch EA,
et  al. Innate defense regulator peptide 1018 in wound healing and wound
infection. PLoS ONE 2012;7:e39373.
36] Tam JP, Lu YA, Yang JL, Chiu KW.  An unusual structural motif of antimicrobial
peptides containing end-to-end macrocycle and cystine-knot disulﬁdes. Proc
Natl  Acad Sci U S A 1999;96:8913–8.
37] van der Does AM,  Bogaards SJ, Ravensbergen B, Beekhuizen H, van Dissel
JT,  Nibbering PH. Antimicrobial peptide hLF1-11 directs granulocyte-
macrophage colony-stimulating factor-driven monocyte differentiation
toward macrophages with enhanced recognition and clearance of pathogens.
Antimicrob Agents Chemother 2010;54:811–6.
38] Wan  M,  van der Does AM,  Tang X, Lindbom L, Agerberth B, Haeggstrom
JZ.  Antimicrobial peptide LL-37 promotes bacterial phagocytosis by human
macrophages. J Leukoc Biol 2014;95:971–81.
39] Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to deter-
mine the minimal inhibitory concentration (MIC) of antimicrobial substances.
Nat Protoc 2008;3:163–75.
40] Wu WJ,  Raleigh DP. Local control of peptide conformation: stabilization
of cis proline peptide bonds by aromatic proline interactions. Biopolymers
1998;45:381–94.
41] Zaleski KJ, Kolodka T, Cywes-Bentley C, McLoughlin RM,  Delaney ML, Charlton
BT,  et al. Hyaluronic acid binding peptides prevent experimental staphylococcal
wound infection. Antimicrob Agents Chemother 2006;50:3856–60.
